Atlas Trials

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Clinical trial NCT04903626 · COMPLETED

Trial details

NCT number
NCT04903626
Sponsor
AbbVie
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatitis C Virus (HCV)
Start date
2021-08-24
Primary completion
2024-09-17
Enrollment
286

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.